WELL Health Q3 revenue misses estimates, reaffirms guidance

WELL Health Technologies

06/11/2025 12:32

Overview

WELL Health Q3 revenue grows 56% yr/yr but misses analyst expectations

Adjusted EBITDA for Q3 rises 296% to C$59.9 mln

Company reaffirms annual revenue and adjusted EBITDA guidance

Outlook

WELL reaffirms 2025 revenue guidance of C$1.40 bln to C$1.45 bln

Company expects 2025 Adjusted EBITDA in upper half of C$190 mln to C$210 mln

WELL's guidance sensitive to M&A and divestitures timing

Result Drivers

CANADIAN PERFORMANCE - Strong performance in core Canadian businesses drove record revenue and adjusted EBITDA

TECHNOLOGY INTEGRATION - AI-enabled technology improved operational efficiency and patient visit metrics

WELLSTAR GROWTH - WELLSTAR subsidiary's growth supported by recent financing and strategic initiatives

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
C$364.60 mln
C$374.50 mln (14 Analysts)
Q3 Adjusted EPS
C$0.16
Q3 Adjusted Net Income
C$41 mln
Q3 Net Income
-C$2.65 mln
Q3 Adjusted EBITDA
C$59.92 mln
Q3 Adjusted Gross Margin
45.50%
Q3 Adjusted Gross Profit
C$165.77 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for WELL Health Technologies Corp is C$7.80, about 37.2% above its November 5 closing price of C$4.90

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 28 three months ago

Press Release: ID:nBw30YvCPa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)